Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. Alzheimer's & dementia : the journal of the Alzheimer's Association Touroutoglou, A., Katsumi, Y., Brickhouse, M., Zaitsev, A., Eckbo, R., Aisen, P., Beckett, L., Dage, J. L., Eloyan, A., Foroud, T., Ghetti, B., Griffin, P., Hammers, D., Jack, C. R., Kramer, J. H., Iaccarino, L., Joie, R. L., Mundada, N. S., Koeppe, R., Kukull, W. A., Murray, M. E., Nudelman, K., Polsinelli, A. J., Rumbaugh, M., Soleimani-Meigooni, D. N., Toga, A., Vemuri, P., Atri, A., Day, G. S., Duara, R., Graff-Radford, N. R., Honig, L. S., Jones, D. T., Masdeu, J. C., Mendez, M. F., Musiek, E., Onyike, C. U., Riddle, M., Rogalski, E., Salloway, S., Sha, S., Turner, R. S., Wingo, T. S., Wolk, D. A., Womack, K., Carrillo, M. C., Rabinovici, G. D., Apostolova, L. G., Dickerson, B. C. 2023

Abstract

Magnetic resonance imaging (MRI) research has advanced our understanding of neurodegeneration in sporadic early-onset Alzheimer's disease (EOAD) but studies include small samples, mostly amnestic EOAD, and have not focused on developing an MRI biomarker.We analyzed MRI scans to define the sporadic EOAD-signature atrophy in a small sample (n = 25) of Massachusetts General Hospital (MGH) EOAD patients, investigated its reproducibility in the large longitudinal early-onset Alzheimer's disease study (LEADS) sample (n = 211), and investigated the relationship of the magnitude of atrophy with cognitive impairment.The EOAD-signature atrophy was replicated across the two cohorts, with prominent atrophy in the caudal lateral temporal cortex, inferior parietal lobule, and posterior cingulate and precuneus cortices, and with relative sparing of the medial temporal lobe. The magnitude of EOAD-signature atrophy was associated with the severity of cognitive impairment.The EOAD-signature atrophy is a reliable and clinically valid biomarker of AD-related neurodegeneration that could be used in clinical trials for EOAD.We developed an early-onset Alzheimer's disease (EOAD)-signature of atrophy based on magnetic resonance imaging (MRI) scans. EOAD signature was robustly reproducible across two independent patient cohorts. EOAD signature included prominent atrophy in parietal and posterior temporal cortex. The EOAD-signature atrophy was associated with the severity of cognitive impairment. EOAD signature is a reliable and clinically valid biomarker of neurodegeneration.

View details for DOI 10.1002/alz.13466

View details for PubMedID 37850549